1Yarker YE, Guo KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability[J].Drug Aging,1995,6:243-262.
2Msselink EJ. Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist[J].BJU Int,1999,83(Suppl 2):48-52.
3Jonas U, Hofner K, Madersbacher H, et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation[J].World J Urol,1997,15:144-15
4Perkash I. Long-term urologic management of the patient with spinal cord injury[J].Urol Clin North Am,1993,20:423-434.
5Giannantoni A, Scivoletto G, Di Stasi SM, et al. Clean intermittent catheterization and prevention of renal disease in spinal cord injury patients[J].Spinal Cord,1998,36:29-32.
6Ruscin JM, Morgenstern NE. Tolterodine use for symptoms of overactive bladder[J].Ann Pharmacother,1999,33:1073-1082.
7胡亚美,江载芳.诸福棠实用儿科学.7版.北京:人民卫生出版社,2002:823-824
8Hellstrom AL, Hanson E, Hansson S, et al. Micturition habits and incontinence in 7-year-old Swedish school entrants. Eur J Pediatr, 1990, 149: 434-437.
9Curran MJ, Kaefer M, Peters C, et al. The overactive bladder in childhood: Long- term results with conservative management. J Urol, 2000,163 : 574-577.
10Phillips E, Uehling DT. Hinman syndrome: A vicious cycle. Urology, 1993, 42:317-319.
